Morgan Stanley 13D and 13G filings for Arcutis Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-06 4:00 pm Sale | 2024-09-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT | MORGAN STANLEY MS | 3,993,787 3.400% | -2,099,710 (-34.46%) | Filing |
| 2024-02-12 09:52 am Purchase | 2023-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | MORGAN STANLEY MS | 6,093,497 6.500% | 6,093,497 (New Position) | Filing |